Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Expands By 26.1%

Kalaris Therapeutics Inc. (NASDAQ:KLRS) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 503,479 shares, an increase of 26.1% from the November 30th total of 399,288 shares. Currently, 10.8% of the shares of the company are sold short. Based on an average daily trading volume, of 145,440 shares, the short-interest ratio is currently 3.5 days. Based on an average daily trading volume, of 145,440 shares, the short-interest ratio is currently 3.5 days. Currently, 10.8% of the shares of the company are sold short.

Analysts Set New Price Targets

Several research firms recently issued reports on KLRS. Citizens Jmp began coverage on Kalaris Therapeutics in a research report on Monday, November 3rd. They issued a “market outperform” rating and a $20.00 target price on the stock. Raymond James Financial began coverage on Kalaris Therapeutics in a report on Tuesday, September 2nd. They issued a “strong-buy” rating on the stock. Wall Street Zen upgraded Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th. Chardan Capital started coverage on Kalaris Therapeutics in a research report on Tuesday, December 23rd. They issued a “buy” rating and a $19.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kalaris Therapeutics in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Kalaris Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $14.00.

Institutional Investors Weigh In On Kalaris Therapeutics

Several hedge funds have recently modified their holdings of the company. Woodline Partners LP acquired a new position in Kalaris Therapeutics in the 3rd quarter worth about $1,394,000. Belpointe Asset Management LLC acquired a new stake in Kalaris Therapeutics in the third quarter valued at approximately $231,000. Fortis Capital Advisors LLC purchased a new stake in shares of Kalaris Therapeutics in the third quarter valued at approximately $231,000. XTX Topco Ltd acquired a new position in shares of Kalaris Therapeutics during the 2nd quarter worth approximately $65,000. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Kalaris Therapeutics during the 3rd quarter valued at approximately $130,000. 66.05% of the stock is owned by hedge funds and other institutional investors.

Kalaris Therapeutics Stock Down 8.2%

Kalaris Therapeutics stock opened at $8.38 on Wednesday. Kalaris Therapeutics has a 52 week low of $2.14 and a 52 week high of $12.90. The firm has a market cap of $156.71 million, a price-to-earnings ratio of -2.22 and a beta of -0.04. The business’s 50-day moving average price is $6.63 and its 200 day moving average price is $4.67.

Kalaris Therapeutics (NASDAQ:KLRS) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.02.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.